DexCom, Inc. (NASDAQ:DXCM) EVP Michael Jon Brown Sells 10,000 Shares

DexCom, Inc. (NASDAQ:DXCM - Get Free Report) EVP Michael Jon Brown sold 10,000 shares of the company's stock in a transaction on Friday, May 23rd. The shares were sold at an average price of $84.28, for a total value of $842,800.00. Following the completion of the transaction, the executive vice president now owns 95,602 shares of the company's stock, valued at $8,057,336.56. This trade represents a 9.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Michael Jon Brown also recently made the following trade(s):

• On Wednesday, March 12th, Michael Jon Brown sold 13,000 shares of DexCom stock. The stock was sold at an average price of $70.38, for a total transaction of $914,940.00.

DexCom Stock Up 1.3%

Shares of DXCM traded up $1.10 on Friday, reaching $85.96. The stock had a trading volume of 4,257,051 shares, compared to its average volume of 4,370,190. The firm has a market capitalization of $33.71 billion, a price-to-earnings ratio of 60.11, a price-to-earnings-growth ratio of 2.30 and a beta of 1.43. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The company has a 50-day simple moving average of $74.67 and a 200-day simple moving average of $78.65. DexCom, Inc. has a 12-month low of $57.52 and a 12-month high of $121.47.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The company had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.02 billion. DexCom had a net margin of 14.29% and a return on equity of 30.14%. The firm's quarterly revenue was up 12.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.32 EPS. Sell-side analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on DXCM shares. Canaccord Genuity Group upped their price target on DexCom from $103.00 to $106.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. Barclays upped their target price on DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a research note on Monday, May 5th. The Goldman Sachs Group assumed coverage on DexCom in a research report on Friday. They set a "buy" rating and a $104.00 price objective on the stock. Cfra Research upgraded DexCom to a "hold" rating in a research report on Friday, March 21st. Finally, Morgan Stanley raised their price target on DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a research report on Friday, February 14th. Five analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $98.32.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in DXCM. Congress Asset Management Co. increased its holdings in shares of DexCom by 5,456.9% in the 4th quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company's stock worth $105,529,000 after purchasing an additional 1,332,522 shares in the last quarter. Proficio Capital Partners LLC purchased a new position in DexCom during the fourth quarter valued at $5,812,000. Fifth Third Bancorp lifted its position in shares of DexCom by 21.5% in the fourth quarter. Fifth Third Bancorp now owns 31,347 shares of the medical device company's stock valued at $2,438,000 after acquiring an additional 5,553 shares in the last quarter. SBI Securities Co. Ltd. purchased a new position in shares of DexCom in the fourth quarter valued at about $49,000. Finally, Flagship Harbor Advisors LLC purchased a new position in shares of DexCom in the fourth quarter valued at about $454,000. Hedge funds and other institutional investors own 97.75% of the company's stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.